TICKERNERD
Menu
AMPHAMPHHealthcare · Drug Manufacturers - Specialty & Generic

AMPH Stock Forecast: Amphastar Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$22
−0.37% on the day

The 7 Wall Street analysts covering Amphastar Pharmaceuticals, Inc. hold a median 12-month price target of $21 — -2.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 22 Aug 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$918.8M
Ticker Nerd rank
84 / 100
Median analyst target
$21
Analysts covering
7
Total return, dividends reinvested
1W
+3.3%
1M
+10.3%
YTD
−19.3%
1Y
−27.2%
From 52W high
−29.9%
From 52W low
+28.0%
$17
$31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AMPH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Amphastar Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
84 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Volatility
80
Quality
74
Revisions
74
Accruals
72
Issuance
72
Size
46
Momentum
38
Growth
32

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (32): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AMPH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AMPH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30Oct 25Jan 26Apr 26Jul 26AMPHHigh $30Median $21Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
0 Buy6 Hold1 Sell
Low $20Median $21High $30

The green dot is the last close — the median target sits −2.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
18 Aug 2026BarclaysMaintainsEqual-Weight$20 → $23
7 Aug 2026Piper SandlerMaintainsNeutral—
7 Aug 2026Piper SandlerMaintainsNeutral$21 → $20
7 Aug 2026Wells FargoMaintainsEqual-Weight—
7 Aug 2026Wells FargoMaintainsEqual-Weight$19 → $20
29 June 2026B of A SecuritiesDowngradeUnderperform$25 → $20
29 June 2026B of A SecuritiesDowngradeUnderperform—
3 June 2026BarclaysMaintainsEqual-Weight—
14 May 2026Wells FargoDowngradeEqual-Weight—
11 May 2026Piper SandlerReiteratesNeutral—
8 May 2026NeedhamDowngradeHold—
21 Apr 2026JefferiesDowngradeHold—
8 Apr 2026BarclaysMaintainsEqual-Weight—
27 Feb 2026NeedhamMaintainsBuy—
27 Feb 2026Wells FargoMaintainsOverweight—
9 Dec 2025BarclaysInitiatesEqual-Weight—
7 Nov 2025NeedhamMaintainsBuy—
22 Oct 2025NeedhamReiteratesBuy—
26 Aug 2025B of A SecuritiesMaintainsNeutral—
12 Aug 2025NeedhamUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMPH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AMPH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.0%
Analysts raising
2
Analysts cutting
2
Fundamentals

Amphastar Pharmaceuticals, Inc. (AMPH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
12.8×

Cheaper than 52% of US stocks

Price / sales
1.3×

Cheaper than 65% of US stocks

Price / book
1.2×

Cheaper than 68% of US stocks

EV / EBITDA
6.8×

Cheaper than 49% of US stocks

Growth & margins
Revenue growth (YoY)
5.4%

Higher than 40% of US stocks

Earnings growth (YoY)
−2.2%

Higher than 33% of US stocks

Gross margin
50.8%

Higher than 63% of US stocks

Operating margin
21.6%

Higher than 81% of US stocks

Net margin
10.8%

Higher than 71% of US stocks

Returns & dividend
Return on equity
10.3%

Higher than 64% of US stocks

Return on assets
5.1%

Higher than 77% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AMPH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
AMPHAmphastar Pharmaceuticals, Inc.$918.8M
84
PCRXPacira Biosciences, Inc.$998.9M
99
COLLCollegium Pharmaceutical, Inc.$857.0M
80
GLASGlass House Brands, Inc.$810.6M
46
IRWDIronwood Pharmaceuticals, Inc.$699.5M
100
TLRYTilray Brands, Inc.$659.2M
18
PAHCPhibro Animal Health Corp.$1.5B
89

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Amphastar Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AMPH news & analysis

New Strong Sell Stocks for August 14th

Zacks Investment Research · 14 Aug 2026negative

Zacks Investment Research added Amphastar Pharmaceuticals, Inc. (AMPH) to its Zacks Rank #5 (Strong Sell) List on August 14, 2026, alongside CHT and HE. The designation reflects a poor near-term outlook assigned by Zacks' ranking system.

Why it matters — AMPH watchers would care because receipt of a Zacks Strong Sell rating indicates a weak near-term assessment from a widely followed research service that could influence investor perception of the stock.

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the transcript of Amphastar Pharmaceuticals' Q2 2026 earnings call. The item reports the company's second-quarter 2026 financial results discussion as presented during the earnings call.

Why it matters — The Q2 2026 earnings call transcript provides AMPH investors with a direct account of the company's recent quarterly performance and management commentary.

Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics

Zacks Investment Research · 7 Aug 2026neutral

Zacks Research reports on Amphastar's Q2 2026 earnings, noting that while revenue and EPS indicate how the business performed, key metrics should be compared against Wall Street estimates and year-ago figures.

Why it matters — Amphastar watchers can gauge how the company's quarterly results measured up against analyst expectations and prior-year performance.

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates

Zacks Investment Research · 7 Aug 2026positive

Amphastar Pharmaceuticals reported Q2 earnings of $0.91 per share, surpassing the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.85 per share in the same quarter a year ago.

Why it matters — The company beat analyst expectations and improved its earnings year over year, indicating stronger-than-anticipated quarterly performance for AMPH.

Amphastar Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026neutral

Amphastar Pharmaceuticals reported second-quarter 2026 revenue growth, supported by recently launched products including ipratropium bromide inhalation. Management noted it is addressing an FDA warning letter at its IMS subsidiary while continuing investments in its pipeline and U.S. manufacturing operations.

Why it matters — AMPH watchers would care because the update covers revenue growth drivers, an ongoing FDA compliance issue at the IMS subsidiary, and the company's continued investment priorities.

FAQ

Frequently asked questions about AMPH stock

What is the AMPH stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Amphastar Pharmaceuticals, Inc. have a median 12-month price target of $21, with estimates ranging from $20 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AMPH stock a buy right now?

Of the 7 analysts covering Amphastar Pharmaceuticals, Inc., 0 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Amphastar Pharmaceuticals, Inc. 84 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AMPH?

As at 22 Aug 2026, Amphastar Pharmaceuticals, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will AMPH stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies -2.8% from the last close, and Ticker Nerd's factor model ranks Amphastar Pharmaceuticals, Inc. 84 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AMPH stock forecast for 2030?

No analyst covering Amphastar Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $30 over the next 12 months.

How has AMPH stock performed over the past year?

Amphastar Pharmaceuticals, Inc. returned -27.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Amphastar Pharmaceuticals, Inc. do?

Amphastar Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development, manufacturing, and marketing of generic and proprietary injectable, intranasal, and inhalation products.

What is the latest news on AMPH?

The most recent item we track (Zacks Investment Research, 14 Aug 2026): "New Strong Sell Stocks for August 14th". Zacks Investment Research added Amphastar Pharmaceuticals, Inc. (AMPH) to its Zacks Rank #5 (Strong Sell) List on August 14, 2026, alongside CHT and HE. The designation reflects a poor near-term outlook assigned by Zacks' ranking system.

Company

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development, manufacturing, and marketing of generic and proprietary injectable, intranasal, and inhalation products. Its portfolio includes technically challenging medications such as BAQSIMI, the leading prescribed nasal spray glucagon for treating severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation aerosol for mild asthma symptoms; enoxaparin for preventing deep vein thrombosis; naloxone and REXTOVY for opioid overdose reversal; glucagon emergency kits; and Cortrosyn for diagnosing adrenocortical insufficiency. Additional offerings encompass Amphadase hyaluronidase injections, epinephrine for allergic reactions, lidocaine formulations for anesthesia, phytonadione for newborns, morphine for pain management, and lorazepam for procedures. These products serve hospital, urgent care, emergency medical services, and retail pharmacy channels, distributed via group purchasing organizations and wholesalers. Operating from state-of-the-art cGMP-compliant facilities, primarily in the United States with presence in China and France, Amphastar Pharmaceuticals Inc. focuses on one reportable segment: pharmaceutical products, emphasizing complex generics, biologics, biosimilars, and innovative drug delivery systems. Founded in 1996 and headquartered in Rancho Cucamonga, California, it plays a vital role in addressing critical medical needs in the specialty pharmaceutical sector.

CEO Dr. Yongfeng Zhang Ph.D. · 2,028 employees · United States · https://www.amphastar.com